H2 2020 Pipeline Review for Beta Nerve Growth Factor - ResearchAndMarkets.com

The "Beta Nerve Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 10 molecules. The latest report Beta Nerve Growth Factor - Pipeline Review, H2 2020, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 4 and 1 respectively.

The report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders and Immunology which include indications Osteoarthritis Pain, Pain, Cancer Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathic Pain, Glaucoma, Keratitis, Low Back Pain, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
• The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

1. Introduction

• Report Coverage

2. Beta Nerve Growth Factor (Beta NGF or NGF) - Overview

3. Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies

4. Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

5. Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

• AstraZeneca Plc
• Fujimoto Pharmaceutical Corp
• MimeTech Srl
• Pfizer Inc
• Regeneron Pharmaceuticals Inc
• Serometrix LLC
• Staidson BioPharma Inc
• Zhuhai Trinomab Biotechnology Co Ltd

6. Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

• fasinumab - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• MEDI-7352 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Monoclonal Antibodies to Inhibit Nerve Growth Factor for Pain - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• MT-2 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products

7. Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products

8. Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

• Featured News & Press Releases

9. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dd4oq2

View source version on businesswire.com: https://www.businesswire.com/news/home/20201016005537/en/